Interleukin-3 (IL-3) receptor α (IL-3Rα) is the α subunit of the
ligand-specific IL-3R and initiates intracellular signaling in response to
IL-3.
IL-3 amplifies proinflammatory signaling and
cytokine storm in murine
sepsis models. Here we found that RNFT2 (RING finger transmembrane-domain containing
protein 2, also TMEM118), a previously uncharacterized RING finger
ubiquitin E3 ligase, negatively regulated IL-3-dependent cellular responses through IL-3Rα ubiquitination and degradation in the
proteasome. In vitro,
IL-3 stimulation promoted IL-3Rα proteasomal degradation dependent on RNFT2, and we identified IL-3Rα
lysine 357 as a
ubiquitin acceptor site. We determined that LPS priming reduces RNFT2 abundance, extends IL-3Rα half-life, and sensitizes cells to the effects of
IL-3, acting synergistically to increase proinflammatory signaling. In vivo,
IL-3 synergized with LPS to exacerbate
lung inflammation in LPS and Pseudomonas aeruginosa-challenged mice; conversely,
IL-3 neutralization reduced LPS-induced
lung injury. Further, RNFT2 overexpression reduced
lung inflammation and injury, whereas Rnft2 knockdown exacerbated inflammatory responses in LPS-induced murine
lung injury. Last, we examined RNFT2 and IL-3Rα in human lung explants from patients with
cystic fibrosis and also showed that
IL-3 is elevated in mechanically ventilated
critically ill humans at risk for
acute respiratory distress syndrome. These results identify RNFT2 as a negative regulator of IL-3Rα and show a potential role for the RNFT2/IL-3Rα/IL-3 axis in regulating innate immune responses in the lung.